Abstracts tagged "prescribing trends and systemic lupus erythematosus (SLE)"

Abstract Number: 2614 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine Initiation Dosing Trends and Predictors in Systemic Lupus Erythematosus
April Jorge¹, Leo Lu², Yuqing Zhang³, Sharan K. Rai⁴, Lucy H. Young⁵, Ronald B. Melles⁶, Michael F. Marmor⁷, Karen H. Costenbader⁸, Rosalind Ramsey-Goldman⁹, S. Sam Lim¹⁰, John M. Esdaile¹¹, Ann E. Clarke¹², Murray Urowitz¹³, Anca Askanase¹⁴, Cynthia Aranow¹⁵, Michelle Petri¹⁶ and Hyon K. Choi⁴, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Department of Ophthalmology,, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ⁶Department of Ophthalmology, Kaiser Permanente, Redwood City, CA, ⁷Department of Ophthalmology and Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, ⁸Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁹FSM, Northwestern University, Chicago, IL, ¹⁰Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ¹¹Arthritis Research Canada, Richmond, BC, Canada, ¹²Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ¹³Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁴Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ¹⁵Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, ¹⁶Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone of systemic lupus erythematosus (SLE) care. The major long-term adverse event risk is vision-threatening toxic retinopathy. The 2012 EULAR,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].